Drugs / Trastzumab Deruxtecan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07340164 | Feb → Dec 2026 expected | ovarian carcinoma | Yonsei University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trastzumab Deruxtecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07340164 ↗ |
| Route | Intravenous | “administrated via intravenous” NCT07340164 ↗ |